Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U; International Working Group on MDS with del(5q). Kuendgen A, et al. Among authors: list af. Leukemia. 2013 Apr;27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21. Leukemia. 2013. PMID: 23257782 Free PMC article.
Chemotherapy resistance in acute myeloid leukaemia.
Sonneveld P, List AF. Sonneveld P, et al. Among authors: list af. Best Pract Res Clin Haematol. 2001 Mar;14(1):211-33. doi: 10.1053/beha.2000.0124. Best Pract Res Clin Haematol. 2001. PMID: 11355932 Review.
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.
Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP. Negoro E, et al. Among authors: list af. Leukemia. 2016 Dec;30(12):2405-2409. doi: 10.1038/leu.2016.228. Epub 2016 Aug 18. Leukemia. 2016. PMID: 27560106 Free PMC article. No abstract available.
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update.
Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, McKenzie D, Beach CL. Silverman LR, et al. Among authors: list af. Ecancermedicalscience. 2008;2:118. doi: 10.3332/ecancer.2008.118. Epub 2008 Dec 8. Ecancermedicalscience. 2008. PMID: 22275990 Free PMC article.
305 results